2022
Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.
Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaMetastatic headCell carcinomaSystemic therapyFirst-line systemic therapyFirst-line immunotherapyInclusion of chemotherapyImmune checkpoint blockadeNew systemic therapiesNumber of patientsAggressive local managementCombination immunotherapyLocoregional therapyOligometastatic diseaseCheckpoint blockadeNovel immunotherapiesPD-L1Lung metastasesRetrospective studyBiomarker subgroupsCurrent therapiesNeck cancerAblative approachesAntiangiogenic agents
2018
Overview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.Peer-Reviewed Original ResearchNeck cancerHPV-negative diseaseImmune checkpoint blockadeSquamous cell cancerHigh recurrence ratePathobiology of headEarly-stage cancerTumor suppressor gene mutationsSuppressor gene mutationsMultimodality therapyCheckpoint blockadeCytotoxic chemotherapyMetastatic diseaseAdvanced cancerCell cancerRecurrence rateHuman papillomavirusDevastating cancerStage cancerSubglottic larynxCancerPersonalized therapyGene mutationsPatientsTherapy